Long-term safety and efficacy demonstrated for GSK's Nucala

7 March 2016

GlaxoSmithKline (LSE: GSK) on Saturday presented positive new safety and efficacy data for Nucala (mepolizumab) from the open-label COSMOS (MEA115661) study at the American Academy of Allergy, Asthma & Immunology annual meeting.

The data shows that the risk/benefit profile generated through the pivotal studies for Nucala was maintained over an extended 52-week period. Exacerbation risk reduction, asthma control improvement and oral corticosteroid dose reduction seen in earlier trials was also demonstrated in the study.

Nucala, which is already approved in the USA and Europe for use in combination with other therapies for patients 12 and older who have a history of severe asthma attacks, is also being tested for the treatment of chronic obstructive pulmonary disease (COPD). Analysts on average expect the drug to generate annual sales of $756 million by 2020, according to Thomson Reuters data, but some believe it has the potential for sales of $1 billion-plus.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK